scispace - formally typeset
M

Martin Bitzan

Researcher at Montreal Children's Hospital

Publications -  71
Citations -  3384

Martin Bitzan is an academic researcher from Montreal Children's Hospital. The author has contributed to research in topics: Escherichia coli & Focal segmental glomerulosclerosis. The author has an hindex of 28, co-authored 65 publications receiving 3048 citations. Previous affiliations of Martin Bitzan include University of Toronto & McGill University Health Centre.

Papers
More filters
Journal ArticleDOI

Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections.

TL;DR: There is an urgent need for effective preventive measures based on a detailed understanding of the epidemiology of ST EC infections, and a survey of laboratory methods currently available for diagnosis of STEC is presented.
Journal ArticleDOI

Non-enteropathic hemolytic uremic syndrome: causes and short-term course.

TL;DR: Although S pneumoniae-related HUS is associated with a less favorable short-term course than other types of non-enteropathic HUS or D+ HUS, the long-term prognosis for recovery of renal function appears to be good in these patients.
Journal ArticleDOI

Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome.

TL;DR: Serological tests and DNA analysis performed by restriction endonuclease digestion of B-subunit toxin genes revealed that all 17 isolates produced Shiga-like toxin II, and a high frequency of sorbitol-fermenting E. coli O157 strains was established in the patients examined.

ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease and Hypertension Non-Enteropathic Hemolytic Uremic Syndrome: Causes and Short-Term Course

TL;DR: In this article, the authors describe the current incidence, causes, demographic features, hospital courses, and short-term outcomes of non-enteropathic HUS and compare them with those obtained from a contemporaneous cohort of children withenteropathic or diarrhea-associated HUS (D HUS) diagnosed and treated at the same clinical sites.